The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...
SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for ...
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FIRE Funds™ have officially launched two new ETFs: the FIRE Funds™ Wealth Builder ETF (FIRS) and the FIRE Funds™ Income Target ETF (FIRI). These actively ...
The Fund is an actively managed exchange-traded fund (ETF) that seeks current income. In particular, the Fund seeks a 4 percent target annual income level (the Annual 4 percent Target). This target ...
Cargo Therapeutics is lightening its load, jettisoning 50% of its employees along with the CAR-T company’s lead candidate in the wake of weak durability and serious side effects. The drug in question, ...
SAN CARLOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Cargo Therapeutics, a developer of cell therapies intended to overcome cancer mechanisms that lead to relapse, is stopping its lead program after a safety complication emerged in a clinical trial that ...
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients. CARGO to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results